Impact of CVOTs in primary and secondary prevention of kidney disease. (November 2019)

• Record Type: Journal Article
• Authors: De Cosmo, Salvatore; Viazzi, Francesca; Piscitelli, Pamela; Leoncini, Giovanna; Mirijello, Antonio; Bonino, Barbara; Pontremoli, Roberto
• Is Part Of: Diabetes research and clinical practice. Volume 157(2019)
• Publication Date: 2019-11
• Subjects: Type 2 diabetes mellitus -- Albuminuria -- Glomerular filtration rate -- Sodium Glucose cotransporter-2 inhibitors (SGLT2-is) -- Glucagon-like peptide-1 receptor agonists (GLP-1ras); Diabetes -- Periodicals; Diabetes Mellitus -- Periodicals; 616.462
• DOI: 10.1016/j.diabres.2019.107907
• Languages: English
• ISSNs: 0168-8227

Abstract

Abstract: Type 2 diabetes mellitus is the leading cause of end stage renal disease worldwide. Diabetic kidney disease, whose main clinical manifestations are albuminuria and decline of glomerular filtration rate, affects up to 40% of patients. Sodium Glucose cotransporter-2 inhibitors (SGLT2-is) and Glucagon-like peptide-1 receptor agonists (GLP-1ras) are new classes of anti-hyperglycemic drugs which have demonstrated to improve renal outcome. Renal benefits of both SGLT2-is and GLP-1ras are acknowledged from data of large randomized phase III clinical trials conducted to assess their cardiovascular safety. In this review, we will focus on renal results of major cardiovascular outcome trials, and we will describe direct and indirect mechanisms through which they confer renal protection.